Eric Lefkofsky is one of the founders of Groupon and also one of the most influential technology figures in Chicago. Eric Lefkofsky is philanthropic who has contributed lost of dollars to support cancer research. Currently, he is among the team who are looking to pack lots of effort toward innovating smarter approaches in handling cancer and cancer patients. It has been reported that since he ceased working in Groupon, Eric Lefkofsky is working at Tempus, a health startup that is aiming at modernizing cancer treatment.
Operations of Tempus
Tempus is secretly operating under the shadow of Lightbank which is another firm that was founded by Eric Lefkofsky. This implies that he has done a great job in ensuring that the company has enough resources to enable it to undertake its core duties. A close research of the Tempus reveals that Eric Lefkofsky could be the president of the Company. It is however not clear the number of hours that Eric Lefkofsky spends in the company, and it appears like he is not willing to disclose it anytime soon.
Tempus’ website states that its primary duty is to help doctors make the most accurate medical decisions which are enhanced by generic code in the context of molecular therapies. By using genomic sequencing, Tempus is able to generate data that can be used to understand the right procedures to be given to cancer patients to avoid errors in handling them. This technology is believed to augment the doctor’s understanding of the patients’ tumour. Tempus uses and collects data that is used in analyzing numerous amounts of genomic information with the aim of uncovering opportunities that are used to assist physicians in making informed decisions when dealing with patients infected with cancer.
Eric Lefkofsky is one of the most dedicated individuals who is working tirelessly to ensure that cancer is brought under human control. It is worth noting that Eric Lefkofsky is such a skilled guy who can work with big organizations; instead, he spends his time doing something unique that would eventually save lives. That is why he has become so influential among the people who are looking to emulate his skills and art of leveraging technology with a positive mindset.
Visit More : www.tempus.com/about-us/
Eric Lefkofsky is the co-founder and head Chief Executive Officer at Tempus. Tempus is a technology company that has built an operating system to explore and customize preventive measures of cancer treatments plan. Tempus Company licenses doctors to deliver personalized cancer care through its dependent analytical and machine learning platform. The company offers an interdisciplinary field of science within the field of molecular biology. The firm also sequences services requested and analyzes little and remedial data to authorize physicians to deliver real-time, decisions that can be backed up with valid data. Tempus primary goal is to make sure all cancer patients benefit from the treatment.
In recent time, Eric Lefkofsky latest startup announced a significant breakthrough as a result of over seventy million in its C funding system from investors Revolution Growth and New Enterprise Associates. The companies have also funded Robinhood and Sweetgreen respectively.
In addition to the company breakthrough, Tempus has joined several partnerships with significant clinics such as the Mayo together with the Cleveland. Additionally, Tempus has also partnered with Duke University School of Medicine, among others. The company made a significant announcement earlier that it is funding and constructing the world most extensive clinical library to enhance and improve cancer care.
Eric Lefkofsky graduated from the University of Michigan with a bachelor degree in law. He began his career by selling all kind of carpets. Eric has since cofounded several ventures including Lightbank, a Chicago based investment capital firm with his lifelong friend. Eric also co-founded Groupon, an international e-commerce platform. Additionally, he is also a co-founder of Uptake Technologies, a nuclear analysis program for the world’s biggest industries. Other ventures that he has co-founded include the Mediaocean, Echo Global Logistics together with Inner Workings which is a global provider of engineered copy and advertising solutions.
Eric Lefkofsky also affiliates himself with many board committees such as the Lurie Children’s Hospital of Chicago together with The Art Institute of Chicago. In addition to his current work, he is also a part-time professor the University of Chicago. Eric additionally heads the Board of Trustees of Chicago’s Steppenwolf Theatre as the director.
Eric Lefkofksy has made a name for himself as one of the Chicago area’s most successful tech entrepreneurs. After having founded Groupon, an innovative company that uses the power of volume purchasing to get group discounts for people in disperse locations across the country, he went on to found a series of other highly successful companies. But then his wife was diagnosed with advanced breast cancer in 2013.
Over the course of the next year, Lefkofsky accompanied his wife to her medical appointments. He was distraught to find out that, often times, oncologists had less access to quality data than did truck drivers or salesmen. He was also surprised to discover the extent to which modern cancer treatments still take a one-size-fits-all approach. If companies like Amazon are capable of generating pages that are highly customized to a user’s preferences, why couldn’t oncology, with the billions and billions spent on it each year, do the same? He set out to research what the answers to those questions were.
Eventually, he came to the conclusion that no single package existed for oncological use that drew from all of the crucial sources of medical data and combined that data into a useful output. In 2016, Lefkofsy founded Tempus, a company dedicated to creating custom analytics for oncologists, enabling the most powerful information available to be put into the clinical setting, in real time.
Tempus makes use of many data sources, including electronic medical records and scientific research papers. But the most important source of the data that the Tempus system relies on is the human genome itself. Lefkofsky explains that the cost of sequencing a single person’s genome has dropped precipitously over the last 14 years. In the year 2003, when the first full human genome was sequenced, the cost was a whopping $100,000,000. Fast forward 14 years and that price tag has plummeted to just $5,000, a 20,000-fold decrease. Eric Lefkofksy projects that number will fall to just a couple hundred dollars in the coming decade.
At such low prices, it will become commonplace for people to have their genome sequenced. Tempus will make optimal use of this data.
Over the course of the past thirty years, Prof. Mikhail Blagosklonny has been striving towards contributing as much as possible in his lifetime to the fight against cancer. He has also been very dedicated to his research in the field of biogerontology or plainly put – the mechanisms of aging. Prof. Mikhail Blagosklonny has been working towards finding a way to slow down and possibly even reverse the process of aging.
- Mikhail Blagosklonny put a start to his journey in the world of science and medicine in his home country of Russia. There, he was a student at a renowned institution called First Pavlov State Medical University. The famous school is located in the second largest city in Russia – St. Petersburg. Prof. Mikhail Blagosklonny graduated from the First Pavlov with both a Ph. D. and an M.D. He majored in Experimental Medicine and Cardiology first, and then in Internal Medicine.
In 2002, Prof. Mikhail Blagosklonny traveled to the United States of America. In New York City, Prof. Mikhail Blagosklonny became a valued member of the New York Medical College where he taught Medicine for a few years. Prof. Mikhail Blagosklonny wished to focus on conducting medical and scientific research, and that prompted him to join another institution that would be able to make it possible for him – the Ordway Research Institute. Prof. Mikhail Blagosklonny was appointed to the position of senior scientists which he occupied for a few years as well. His research was sharply focused on the field of oncology. The research that Prof. Mikhail Blagosklonny was able to conduct at the Ordway Research Institute, however, had a number of restraints. The Institute was not able to support any further research In search of more options; Prof. Mikhail Blagosklonny moved on and took a position at the Roswell Park Cancer Institute. As the name of the institution denotes, Roswell Park is specialized in the research of cancer. Visit classroomvoices.org to read more about Mikhail.
- Mikhail Blagosklonny has been doing research at the Roswell Park Cancer Institute from 2009, and he is still an integral part of the Institute. He has also been able to expand upon his research, and so he has been doing research in biogerontology as well as further his research of the many types of cancer. Prof. Mikhail Blagosklonny is working with many esteemed researchers and scientists.
Along with his scientific and medical research, Prof. Mikhail Blagosklonny has been devoted to his work as an editor and editor in chief. The professor has been an editor in chief of Oncotarget along with one of his colleagues from the Roswell Park Cancer Institute. He has also been an editor of Cell Cycle and Aging – two other online medical journals. Prof. Mikhail Blagosklonny has also written a plethora of articles and papers on a variety of medical and scientific topics. His written work amasses to more than a hundred pieces. Most of them encompass the topics of biogerontology and oncology and talk about his research up until that point and the overall progression and future of his research. Read more on templeofthecave.com
Seattle Genetics is among the majority of the companies making interesting discoveries in the field of cancer research. Dr. Siegall, CEO of Seattle Genetics, has been ardent on enhancing treatment for cancer patients since starting his career in biomedical studies. He has led this innovative company for approximately two decades. Dr. Siegall’s hardwork and determination has greatly contributed to advancements in cancer research and therapies for cancer patients.
Siegall amassed many professional accomplishments since getting his Ph.D. in Genetics from George Washington University. His career started as a senior research investigator at the Bristol-Myers Squibb Pharmaceuticals Research Institute. Before becoming the staff and biotechnology fellow at the National Cancer Institute, he was promoted to being the principal scientist.
Seattle Genetics developed the first antibody-drug conjugates (ADCs) and ADCETRIS, which got approved by FDA in 2011. Currently, ADCETRIS is now available to cancer patients in more than 60 countries around the world. Siegall helped to fundraise over $1.2billion in both public and private funding. The funds were to finance Seattle Genetics in paving way for advanced cancer treatments using innovative technology.
Dr. Siegall was awarded the University of Maryland Alumnus of the Year for Math, Computer and Natural Sciences in 2013. In 2012, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year. These awards were meant to recognize his significant contributions to the medical and scientific communities. Siegall currently hold 15 patents and continues to search for new ways in medical research. He has published over 70 scientific articles and still shares his knowledge with the medical and scientific communities.
Clay Siegall is an enthusiast of science and technology. In 1998, he co-founded Seattle Genetics. Currently, he is the president, CEO and chairman of the board at Seattle Genetics. The company is growing since their stock price tripled in a span of 5 years. This growth is all because of Clay’s interest in drug development, scientific innovations, research and importantly helping patients.
The Seaport World Trade Center’s Pegs Boston interviewed Siegall concerning the future he envisioned for Seattle Genetics. He said that the company had made a couple of drugs SGN-CD33A and SGN-CD19A. The drugs are designed to target Leukemia cells and stabilize the bloodstream to enable the flushing out of cytotoxic agents.